MedPath

FDA Approves Zeiss MEL 90 Excimer Laser and Accepts Revised sNDA for Izervay

This week, the FDA approved the Zeiss MEL 90 excimer laser for myopia, hyperopia, and mixed astigmatism, and accepted a revised supplemental New Drug Application for Izervay, targeting geographic atrophy secondary to age-related macular degeneration. Additionally, a new report from The Vision Council sheds light on eye care providers' frame buying habits, and a study highlights the link between dietary inflammation and non-refractive visual impairment.

FDA Approves Zeiss MEL 90 Excimer Laser

The FDA has granted approval to the excimer laser MEL 90 from Zeiss Meditech, marking a significant advancement in the treatment of myopia, hyperopia, and mixed astigmatism. This laser integrates seamlessly into the Corneal Refractive Workflow from Zeiss, complementing the Visumax 800 and SMILE pro software to enhance surgical correction outcomes. The MEL 90 is now available in the US, offering a streamlined approach to refractive surgery.

Revised Supplemental New Drug Application for Izervay Accepted

In another pivotal development, the FDA has accepted the revised supplemental New Drug Application (sNDA) for Izervay (avacincaptad pegol intravitreal solution), aimed at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This acceptance follows a Complete Response Letter from the FDA in November 2024 and a subsequent meeting between the FDA and Astellas. The application has been designated as a Class 1 resubmission, with a target action date set for February 26, 2025.

Insights into Eye Care Providers' Frame Buying Habits

A new research report from The Vision Council, titled 'Focused inSights 2024: Frame Buyers,' provides an in-depth analysis of how eye care providers select and source eyeglasses frames. The report covers various aspects, including the frequency of purchases, sourcing locations, and preferences for frame styles and materials, offering valuable insights into the industry's supply chain dynamics.

Dietary Inflammatory Index Linked to Non-Refractive Visual Impairment

A study conducted by Chinese researchers has identified a positive association between the Dietary Inflammatory Index (DII) and non-refractive visual impairment in the US population. This type of visual impairment results from ocular diseases rather than the eye's shape, highlighting the importance of dietary considerations in eye health.

AOA Releases Clinical Practice Guideline for POAG

The American Optometric Association (AOA) has published the first edition of 'Care of the Patient with Primary Open-Angle Glaucoma,' an evidence-based clinical practice guideline. This guideline aims to enhance the quality of healthcare by providing optometrists with a scientific foundation for diagnosing and treating patients with primary open-angle glaucoma, ensuring that care is based on the latest research.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Advancements in Retina and Vitreous Treatments Highlighted in Recent Studies and Collaborations

Recent developments in the treatment of retinal diseases include strategic collaborations, clinical trials, and studies highlighting advancements in personalized treatment and the increasing prevalence of retinopathy of prematurity.

Galimedix Therapeutics Initiates Phase 1 Trial of Oral GAL-101 for Amyloid Beta Modulation

Galimedix Therapeutics has begun a Phase 1 clinical trial for oral GAL-101, an amyloid beta (Aβ) aggregation modulator, to assess its safety and tolerability.
The trial will evaluate single and multiple ascending doses of GAL-101, an orally administered therapy, focusing on pharmacokinetics.

FDA Issues Complete Response Letter for Astellas' Avacincaptad Pegol; Aldeyra's Reproxalap NDA Accepted

The FDA issued a Complete Response Letter for Astellas Pharma's avacincaptad pegol intravitreal solution, indicating the sNDA cannot be approved in its current form.
Aldeyra Therapeutics' resubmitted NDA for topical ocular reproxalap, a first-in-class investigational candidate for dry eye disease, has been accepted by the FDA.

FDA Issues Complete Response Letter for Astellas' IZERVAY and Accepts Aldeyra's NDA for Reproxalap

The FDA issued a Complete Response Letter for Astellas' IZERVAY (avacincaptad pegol) due to a statistical matter regarding proposed labeling language, unrelated to safety or efficacy.
Aldeyra Therapeutics' resubmitted New Drug Application (NDA) for reproxalap, a topical ocular treatment for dry eye disease, has been accepted by the FDA.

AAO 2024 Highlights: Aging Clinicians, Presbyopia Drop, Modern Anesthesia, and AMD Advancements

Alfredo Sadun, MD, addressed the challenges of aging clinicians in ophthalmology, highlighting the complexities of assessing competency and avoiding ageism.
Jennifer Loh, MD, presented data on CSF-1, a low-dose pilocarpine drop, demonstrating a 30% mean reduction in pupil size and improved near visual acuity without affecting distance vision.

LENZ Therapeutics' LNZ100 NDA Accepted by FDA for Presbyopia Treatment

The FDA has accepted the New Drug Application (NDA) for LENZ Therapeutics' LNZ100, a potential treatment for presbyopia.
The NDA is supported by Phase 3 CLARITY study data, which demonstrated significant near vision improvement in participants.

FDA Accepts Lenz Therapeutics' LNZ100 for Presbyopia Treatment, PDUFA Date Set

The FDA has accepted Lenz Therapeutics' New Drug Application (NDA) for LNZ100, a once-daily eye drop to treat presbyopia, marking a significant regulatory milestone.
LNZ100 contains aceclidine, a muscarinic acetylcholine receptor agonist, potentially improving near vision through a 'pinhole' effect without affecting distance vision.

TENEO Excimer Laser Shows Promising Results in Myopic LASIK

The TENEO excimer laser by Bausch + Lomb, recently FDA-approved, demonstrates excellent safety and efficacy in treating myopia and myopic astigmatism.
A significant portion of patients experienced improved visual acuity after LASIK with the TENEO laser, with many achieving 20/16 vision or better.

Advancements in Ocular Therapies: Updates on Dry Eye, AMD, and Myopia Management

Aldeyra Therapeutics resubmitted its NDA for reproxalap, targeting dry eye disease symptoms with both acute and chronic activity demonstrated in trials.
Aviceda Therapeutics completed enrollment for its Phase 2b SIGLEC study, evaluating AVD-104 for geographic atrophy secondary to age-related macular degeneration.

Positive Phase 3 Data and New Glaucoma Treatments Highlight Advancements in Ophthalmology

A recent clinical trial achieved its primary visual acuity endpoints in both the US and EU/UK, demonstrating statistically significant near vision improvements over 8 hours.
Long-term analysis of a glaucoma treatment shows clinically and statistically significant reductions in intraocular pressure up to 36 months postoperatively.

Reference News

[1]
What happened in optometry this week: January 13 - January 17
optometrytimes.com · Jan 18, 2025

FDA approved Zeiss MEL 90 excimer laser for myopia, hyperopia, and mixed astigmatism. The Vision Council's report analyz...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy